Welcome to REHAB FOR BIG PHARMA!
Forensic analysis on what happens when (not if) Big Pharma collapses
Welcome to Pharma future!
We know what the addictive gambler has done to itself and thousands, if not millions, of innocent people.
Check here if you need reminding:
As already mentioned, the next stage is to follow on from INSIDE PHARMA, with REHAB FOR BIG PHARMA.
The aim is to go further than focusing on what’s gone wrong, important as that has been to raise awareness of how bad this have become. The aim here is to outline a way to develop diagnostic and medical solutions that fit the needs of the individual for health and wellbeing in the 21st Century, and beyond.
I began on this path in 2019, May 8th to be exact, when I (PharmaFlow) hosted a conference in Wales’s Techniquest, the UK’s longest established science centre.
Attendees included clinicians, patients, representatives of relevant charities, experts in product development, legal, regulatory and supply chain management. Numbers were small, but passion for change was unlimited.
The day was organised in workshop format, titled “MEDICINES FOR THE 21st CENTURY: Safe, Better, Cheaper”.
It involved in-depth dialogue and transfer of knowledge, over three panel sessions, between invited attendees and panel members, considering issues and opportunities in relation to safe medicines, better medicines and cheaper medicines.
Proceedings over the day were recorded on video, and live polling was used to collect inputs from those in attendance - see headline video:
MEDICINES FOR THE 21st CENTURY: Safe, Better, Cheaper
Carwyn Jones MS, immediate past First Minister for Welsh Government, presented the Inauguration Address.
Janet Woodcock MD, then Director, CDER, FDA, recorded the Keynote Address, also titled MEDICINES FOR THE 21st CENTURY: Safe, Better, Cheaper.
The priorities Dr Woodcock speaks of in the Address are related to FDAs 2019 priorities, prior to the emergence of SARS-CoV-2.
As many will know, Dr Woodcock was also Acting Commissioner of Food and Drugs from Jan. 20, 2021 until Feb. 17, 2022.
White paper
Output from proceedings was written up as a white paper, produced by me and endorsed by the attendees. Issues and concerns were categorised under the following headings (the paper will be shared in manageable chunks as we go along):
Patient and healthcare professional (HCP) relationship
Screening and prevention
New product development (NPD)
Supply-chain integrity
Intellectual Property Rights (IPR)
Education
Transparency
Education was ranked as the highest priority area at the time—and by golly, didn’t SARS-CoV-2 prove that to be the right decision. How could generations of people not know it takes 10 times longer to develop a safe, effective, quality injection than nine months!!!
Education is the starting point
REHAB FOR BIG PHARMA therefore kicks- off with a healthy dose of education on the pharma industry and drug development, along with its various complexities.
As it happens, over the last 6 months, I have been working with the University of South Wales Schoo